Processa Pharmaceuticals, Inc. — Director's Dealing 2023

Jan 4, 2023

SEC Form 4/A — Form 4/A

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-08-05

Reporting Person: Yorke Justin W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-05	Common Stock	M	1169	—	Acquired	14885	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	532563	Indirect

Footnotes

F1: Vesting of time-based restricted shares.

F2: Previous filing inadvertently underreported shares beneficially owned by the reporting person.